📰 Peter Schmid News
Page 5 - Peter Schmid News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Peter Schmid. Real-time updates on events, politics, business and more.
September 29, 2021
Für 80000 Euro beschafft die Stadt aktuell mobile Luftfiltergeräte für Ludwigsburger Schulen. Viel zu wenig, findet die Elterninitiative „Jedes Kind ...
July 1, 2021
Neuwahlen Neudörfl: Schmid neuer Feuerwehrkommandant. Peter Schmid wird der Nachfolger von Vanessa Pilles als Feuerwehrkommandant, Florian Steurer tritt die Nachfolge von Thomas Stocker als Stellvertreter an. Von Christian Artner. Erstellt am 01. Juli 2021 (04:08) Vizebürgerme...
May 1, 2021
Women with incurable breast cancer have been thrown fresh hope thanks to a ‘mind-blowing’ new drug that holds the disease at bay for more than twice as long as previous treatments. The medication can halt progression for two years, compared to just nine months with previous options, according to the latest trial results. The drug, Enhertu, approved by NHS health chiefs last week, is given every three weeks in hospital via an intravenous drip, and combines two potent compounds: an antibody t...
April 20, 2021
Daiichi Sankyo UK, Limited: ENHERTU - (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER Reimbursement decisions in Scotland, Wales, and Northern Ireland to be announced later this year Daiichi Sankyo UK, Limited (hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer ...
April 20, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation. ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER April 20, 2021 GMT Daiichi Sankyo UK, Limited (hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu ® (trastuzumab deruxtecan) for use within the Cancer Drug...